Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.59 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.55 |
| ▸ | AURKA | O14965 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.53 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.53 |
| ▸ | BCHE | P06276 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Salverine SCHEMBL29360867 | 1.00 | ALDH1A1 (0.70) | ALDH1A1KDM4ELMNAPOLBNPSR1 | |
| Salverine SCHEMBL29375616 | 0.99 | ALDH1A1 (0.68) | ALDH1A1KDM4ELMNAPOLBNPSR1 | |
| SCHEMBL10066976 | 0.86 | RXFP1 (0.64) | ALDH1A1KDM4ELMNAPOLBNPSR1 | |
| Salverine SCHEMBL5886094 | 0.86 | KDM4E (0.54) | ALDH1A1KDM4ELMNAPOLBNPSR1 | |
| SCHEMBL3500700 | 0.86 | MCHR1 (0.59) | ALDH1A1KDM4ELMNAPOLBNPSR1 | |
| SCHEMBL3500563 | 0.86 | MCHR1 (0.59) | ALDH1A1KDM4ELMNANPSR1MCHR1 | |
| SCHEMBL11338177 | 0.83 | ALDH1A1 (0.76) | ALDH1A1KDM4ELMNANPSR1MCHR1 | |
| SCHEMBL11756085 | 0.83 | MCHR1 (0.58) | ALDH1A1KDM4ELMNANPSR1MCHR1 | |
| Hydrochloric Acid SCHEMBL11751328 | 0.82 | MCHR1 (0.57) | ALDH1A1KDM4ELMNANPSR1MCHR1 | |
| Hydrochloric Acid SCHEMBL11671640 | 0.82 | ALDH1A1 (0.74) | ALDH1A1KDM4ELMNAPOLBMCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2560634-A1 | NITRIC OXIDE RELEASING PRODRUGS OF THERAPEUTIC AGENTS | Piramal Enterprises Limited (IN) | 2013-02-27 | — | — | EP | claimed |
| US-20120063996-A1 | NOVEL NIMESULIDE COMPOSITIONS | ELAN PHARMA INTERNATIONAL LTD. | 2012-03-15 | — | — | US | claimed |
| US-20110263526-A1 | Nitric Oxide Releasing Prodrugs of Therapeutic Agents | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-10-27 | — | — | US | claimed |
| WO-2011132171-A1 | NITRIC OXIDE RELEASING PRODRUGS OF THERAPEUTIC AGENTS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-10-27 | — | — | WO | claimed |
| EP-1617816-B1 | NANOPARTICULATE MELOXICAN FORMULATIONS | ELAN PHARMA INT LTD (IE) | 2009-05-13 | — | — | EP | claimed |
| EP-1938803-A2 | Formulations comprising nanoparticulate meloxican | Elan Pharma International Limited (IE) | 2008-07-02 | — | — | EP | claimed |
| CN-100346832-C | Pharmaceutical dosage form for transmucosal delivery | PHARMACIA CORP (US) | 2007-11-07 | — | — | CN | claimed |
| EP-1480624-B1 | PHARMACEUTICAL TABLET | PHARMACIA CORP (US) | 2006-11-29 | — | — | EP | claimed |
| EP-1471890-B1 | PHARMACEUTICAL DOSAGE FORM FOR MUCOSAL DELIVERY | PHARMACIA CORP (US) | 2006-09-27 | — | — | EP | claimed |
| CN-1829510-A | Dispersible formulation of an anti-inflammatory agent | PHARMACIA & UPJOHN CO LTD (US) | 2006-09-06 | — | — | CN | claimed |
| WO-2004082719-A1 | DISPERSIBLE PHARMACEUTICAL COMPOSITION FOR TREATMENT OF MASTITIS AND OTIC DISORDERS | PHARMACIA CORPORATION (US) | 2004-09-30 | — | — | WO | claimed |
| US-20040156872-A1 | Novel nimesulide compositions | ELAN PHARMA INTERNATIONAL LTD. | 2004-08-12 | — | — | US | claimed |
| US-20030235617-A1 | Pharmaceutical dosage form for mucosal delivery | MCNEIL-PPC, INC | 2003-12-25 | — | — | US | claimed |
| US-20030180357-A1 | Pharmaceutical tablet | MCNEIL-PPC, INC | 2003-09-25 | — | — | US | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| WO-2003066029-A2 | PHARMACEUTICAL DOSAGE FORM FOR MUCOSAL DELIVERY | PHARMACIA CORPORATION (US) | 2003-08-14 | — | — | WO | claimed |
| WO-2003066030-A2 | PHARMACEUTICAL TABLET | PHARMACIA CORPORATION (US) | 2003-08-14 | — | — | WO | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040156872-A1 | Novel nimesulide compositions | NIM1K, NIT2, NCL | ALDH1A1 3888/4885KDM4E 1888/4885LMNA 3668/4885 |
| US-20030180357-A1 | Pharmaceutical tablet | GYPA, SORD, SRI | ALDH1A1 1900/4885KDM4E 3204/4885LMNA 2379/4885 |
| US-20120063996-A1 | NOVEL NIMESULIDE COMPOSITIONS | NIM1K, NIT2, NCL | ALDH1A1 3888/4885KDM4E 1888/4885LMNA 3668/4885 |
| US-20110263526-A1 | Nitric Oxide Releasing Prodrugs of Therapeutic Agents | NOS2, NOS1, NOS3 | ALDH1A1 204/4885KDM4E 2388/4885LMNA 3648/4885 |
| US-20030235617-A1 | Pharmaceutical dosage form for mucosal delivery | SI, UGGT1, GYPA | ALDH1A1 1722/4885KDM4E 2862/4885LMNA 2639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.